Halma (HLMA) Trading Update summary

Trading performance and outlook

• Achieved further progress in the first half of FY2025, with varied trading conditions across end markets.

• Maintains guidance for good organic constant currency revenue growth and an adjusted EBIT margin of around 21% for the full year ending March 2025.

• Group order intake year-to-date is ahead of both revenue and the comparable period last year.

• Adjusted EBIT margin expected to be modestly higher than the prior year’s first half, with strong cash performance supporting investments and acquisitions.

• Sterling appreciation is negatively impacting results, with an estimated £56m revenue and £14m profit headwind for FY2025 if current rates persist.

M&A activity and portfolio management

• Completed four acquisitions in the Safety sector in H1 FY2025, totaling approximately £85m in consideration.

• Acquisitions include MK Test Systems (£44m), G.F.E. (€42.5m/£36m), Advantronic (€2.3m/£2m), and RemLive (£3.5m).

• Maintains a healthy acquisition pipeline across all three sectors: Safety, Environment, and Health.

• Disposed of Hydreka SAS for approximately £7m, aligning the portfolio with strategic objectives.

Strategic focus and company profile

• Operates a diversified portfolio of life-saving technology companies focused on safety, environment, and health.

• Employs over 8,000 people in more than 20 countries, with major operations in the UK, Europe, USA, and Asia Pacific.

• Recognized as one of Britain's Most Admired Companies for six consecutive years.

• Half-year results for the period ending 30 September 2024 will be released on 21 November 2024.